Outlook Therapeutics, Inc. (OTLK) - Dilution Analysis

8-K filing: Outlook Therapeutics, Inc. completed a registered direct offering of 8,539,709 shares of common stock to GMS Ventures and Investments.

8-K filing: Outlook Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 8,539,709 shares of common stock at $0.5855 per share and amended existing warrants. ($5.0M proceeds)

10-Q filing | 120.9M shares outstanding

8-K filing: Outlook Therapeutics, Inc. completed a public offering of common stock and warrants on March 25, 2026, issuing 20,000,000 shares of common stock and accompanying warrants at a combined price of $0.25 per share, resulting in gross proceeds of approximately $5.0 million and net proceeds of approximately $4.0 million. ($5.0M proceeds)

10-Q filing | 23.9M shares outstanding

8-K filing: Outlook Therapeutics, Inc. entered into an underwriting agreement for the issuance and sale of 9,285,714 shares of common stock and accompanying warrants to purchase up to 18,571,428 shares of common stock at a combined offering price of $1.40 per share and warrant, with GMS Ventures and Investments committing to purchase shares and warrants for approximately $6.0 million; the offering is expected to close on or about May 27, 2025. ($13.0M proceeds)

10-Q filing | 23.9M shares outstanding

S-3 filing: This S-3 filing registers 21,720,655 shares of common stock for resale by selling stockholders, including shares issuable upon exercise of warrants and conversion of a promissory note.

S-3 filing: The filing is an S-3 registration statement for the offer and resale of up to 7,074,637 shares of common stock issuable upon the exercise of outstanding Tranche A warrants held by the selling stockholders.

10-Q filing | 24.2M shares outstanding

8-K filing: Outlook Therapeutics, Inc. entered into warrant exercise inducement offer letter agreements with certain holders of existing warrants to purchase 7,074,637 shares of common stock at a reduced exercise price of $2.51 per share, in exchange for new warrants to purchase up to 14,149,274 shares of common stock at an exercise price of $2.26 per share; Additionally, Syntone Ventures, LLC agreed to exercise its existing warrants to purchase 1,071,429 shares of Common Stock for an aggregate Reduced Exercise Price of approximately $2.51 in exchange for the Company's agreement to issue new warrants to purchase up to 2,142,858 shares of Common Stock. ($20.5M proceeds)

10-K filing | 23.9M shares outstanding

10-Q filing | 13.0M shares outstanding

10-Q filing | 14.3M shares outstanding

S-3 filing: Resale of common stock by selling stockholder.

8-K filing: Outlook Therapeutics, Inc. closed a private placement with Syntone Ventures LLC, issuing 714,286 shares of common stock and warrants to purchase 1,071,429 shares at $7.00 per share and warrant.

S-3 filing: The company is filing an S-3 to register the offering of common stock, preferred stock, debt securities, and warrants up to a total aggregate offering price of $300,000,000.

S-3 filing: This S-3 filing registers 21,428,556 shares of common stock for resale by selling stockholders, including shares held outright and those issuable upon the exercise of warrants from a private placement on March 18, 2024; the company will not receive proceeds from the sale of these shares, but may receive proceeds from warrant exercises.

10-Q filing | 260.3M shares outstanding

10-K filing | 250.2M shares outstanding

S-3 filing: This is an S-3 filing registering common stock issuable upon the exercise of placement agent warrants, with the company intending to use proceeds from warrant exercises for development, commercialization, working capital and general corporate purposes.

10-Q filing | 256.9M shares outstanding

10-Q filing | 256.7M shares outstanding

10-Q filing | 256.7M shares outstanding

10-K filing | 212.1M shares outstanding

8-K filing: Outlook Therapeutics, Inc. entered into purchase agreements to sell 28,460,831 shares of common stock at $0.8784 per share in a registered direct offering, resulting in gross proceeds of approximately $25 million. ($25.0M proceeds)

8-K filing: Outlook Therapeutics, Inc. entered into a Securities Purchase Agreement with Streeterville Capital, LLC, issuing an unsecured convertible promissory note with a face amount of $31,820,000 for gross proceeds of approximately $30 million, with the closing expected on December 28, 2022. ($30.0M proceeds)

10-Q filing | 220.5M shares outstanding

10-Q filing | 219.1M shares outstanding

10-Q filing | 224.3M shares outstanding

10-K filing | 176.5M shares outstanding

8-K filing: Outlook Therapeutics, Inc. closed a public offering of 40,000,000 shares of common stock at $1.25 per share, with an additional 6,000,000 shares sold upon full exercise of the underwriter's option, resulting in net proceeds of approximately $54.0 million.

10-Q filing | 127.2M shares outstanding

10-Q filing | 173.6M shares outstanding

S-3 filing: The company may offer shares of its common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, up to a total dollar amount of $250,000,000 from time to time under this prospectus.

10-Q filing | 173.4M shares outstanding

8-K filing: Outlook Therapeutics, Inc. sold 1,013,627 shares of Common Stock to GMS Ventures and Investments at a price of $1.00 per share, for gross proceeds of $1,013,627, in a private placement that closed on February 10, 2021. ($1.01M proceeds)

8-K filing: Outlook Therapeutics, Inc. completed a firm commitment offering of 35,000,000 shares of common stock at $1.00 per share on February 2, 2021, with H.C. Wainwright & Co., LLC as the sole book-running manager. ($35.0M proceeds)

10-K filing | 127.2M shares outstanding

10-Q filing | 127.2M shares outstanding

8-K filing: Outlook Therapeutics, Inc. completed a registered direct offering of 8,407,411 shares of common stock at $1.215 per share, resulting in gross proceeds of approximately $10.2 million, and a private placement with Syntone Ventures LLC of 823,045 shares at $1.215 per share, for gross proceeds of approximately $1.0 million. ($11.2M proceeds)

8-K filing: Outlook Therapeutics, Inc. entered into a Stock Purchase Agreement with Syntone Ventures LLC to sell 16,000,000 shares of common stock at $1.00 per share for gross proceeds of $16.0 million. ($16.0M proceeds)

10-Q filing | 91.4M shares outstanding

S-1 filing: This prospectus relates to the resale by the selling stockholders of up to 4,331,103 shares of common stock issuable upon the exercise of certain outstanding warrants.

8-K filing: On March 23, 2020, the Company issued 29,358,621 shares of its common stock upon conversion of 68,112 shares of Series A-1 Preferred outstanding and held by BioLexis Pte. Ltd. Effective March 19, 2020, the Company is issuing an aggregate of 7,244,739 shares of Common Stock to the four principals of MTTR pursuant to the terms of previously disclosed consulting agreements.

8-K filing: Outlook Therapeutics, Inc. entered into securities purchase agreements to sell and issue 7,598,426 shares of common stock at $1.016 per share, and also agreed to sell warrants to purchase up to 3,799,213 shares in a concurrent private placement; GMS Ventures will purchase 2,460,630 shares of common stock and warrants. ($10.22M proceeds)

10-Q filing | 43.1M shares outstanding

8-K filing: Outlook Therapeutics amended warrants held by BioLexis to acquire 4,657,852 shares, reducing the exercise price to $0.232 per share, which BioLexis then exercised for approximately $1.1 million. They also entered into agreements with MTTR LLC to issue shares subject to stockholder approval. ($1.1M proceeds)